BR0314314A - Derivados do éter 4-pirrolidina-fenil-benzìlico - Google Patents

Derivados do éter 4-pirrolidina-fenil-benzìlico

Info

Publication number
BR0314314A
BR0314314A BR0314314-7A BR0314314A BR0314314A BR 0314314 A BR0314314 A BR 0314314A BR 0314314 A BR0314314 A BR 0314314A BR 0314314 A BR0314314 A BR 0314314A
Authority
BR
Brazil
Prior art keywords
pyrrolidine
phenyl
ether derivatives
benzyl ether
derivatives
Prior art date
Application number
BR0314314-7A
Other languages
English (en)
Inventor
Synese Jolidon
Rosa Maria Rodriguez-Sarmiento
Andrew William Thomas
Wolfgang Wostl
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0314314A publication Critical patent/BR0314314A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DO éTER 4-PIRROLIDINA-FENILBENZìLICO". A presente invenção refere-se a derivados de 4-pirrolidina de fórmula (I), racêmicos ou enantiomericamente puros, a processos para sua preparação, composições farmacêuticas compreendendo os ditos derivados e seu uso na prevenção e tratamento de doenças, por exemplo, doenças mediadas pelos inibidores de monoamina oxidase B, em particular, as doenças de Alzheimer e demência senil.
BR0314314-7A 2002-09-20 2003-09-18 Derivados do éter 4-pirrolidina-fenil-benzìlico BR0314314A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010383 WO2004026826A1 (en) 2002-09-20 2003-09-18 4-pyrrolidino-phenyl-benzyl ether derivatives

Publications (1)

Publication Number Publication Date
BR0314314A true BR0314314A (pt) 2005-07-26

Family

ID=32010924

Family Applications (4)

Application Number Title Priority Date Filing Date
BR0314299-0A BR0314299A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b
BR0314631-6A BR0314631A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de maob
BR0314314-7A BR0314314A (pt) 2002-09-20 2003-09-18 Derivados do éter 4-pirrolidina-fenil-benzìlico
BRPI0314631-6A BRPI0314631B1 (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b, seu uso, e composição farmacêutica

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR0314299-0A BR0314299A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b
BR0314631-6A BR0314631A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de maob

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0314631-6A BRPI0314631B1 (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b, seu uso, e composição farmacêutica

Country Status (31)

Country Link
US (4) US7235581B2 (pt)
EP (3) EP1542969B1 (pt)
JP (3) JP4335141B2 (pt)
KR (3) KR100676015B1 (pt)
CN (3) CN100503562C (pt)
AR (3) AR041299A1 (pt)
AT (2) ATE472530T1 (pt)
AU (3) AU2003273901B2 (pt)
BR (4) BR0314299A (pt)
CA (3) CA2496756C (pt)
CY (1) CY1110745T1 (pt)
DE (2) DE60331559D1 (pt)
DK (1) DK1542970T3 (pt)
ES (2) ES2344557T3 (pt)
GT (3) GT200300205A (pt)
HR (3) HRP20050263B1 (pt)
JO (2) JO2605B1 (pt)
MX (3) MXPA05002878A (pt)
MY (3) MY134480A (pt)
NO (3) NO330012B1 (pt)
NZ (3) NZ538049A (pt)
PA (3) PA8583001A1 (pt)
PE (3) PE20050077A1 (pt)
PL (3) PL376018A1 (pt)
PT (1) PT1542970E (pt)
RU (3) RU2323209C2 (pt)
SI (1) SI1542970T1 (pt)
TW (3) TWI286132B (pt)
UY (3) UY27990A1 (pt)
WO (3) WO2004026825A1 (pt)
ZA (3) ZA200501137B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
BRPI0514077A (pt) * 2004-08-02 2008-05-27 Hoffmann La Roche derivados de benzilóxi como inibidores de maob
NZ560232A (en) 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
CA2601416C (en) * 2005-03-15 2013-07-09 F. Hoffmann-La Roche Ag Method for preparing enantiomerically pure 4-pyrrolidinophenyl benzyl ether derivatives
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
WO2008121407A1 (en) * 2007-03-30 2008-10-09 The Regents Of The University Of California In vivo imaging of sulfotransferases
KR101220182B1 (ko) 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
WO2014158916A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
CZ305213B6 (cs) * 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
CN105705487A (zh) * 2013-10-29 2016-06-22 豪夫迈·罗氏有限公司 可用于治疗阿尔茨海默病的吡咯烷酮衍生物的晶形及其制备
ES2912881T3 (es) 2014-12-23 2022-05-30 Convergence Pharmaceuticals Procedimiento para preparar derivados de alfa-carboxamida pirrolidina
CN107223052A (zh) * 2015-03-27 2017-09-29 豪夫迈·罗氏有限公司 包含sembragiline的药物制剂
EP3689870B1 (en) 2017-09-27 2022-07-13 Kagoshima University Analgesic drug using pac1 receptor antagonistic drug
CN112153968A (zh) 2017-10-05 2020-12-29 生物基因公司 制备α-羧酰胺吡咯烷衍生物的工艺
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
EP3762364B1 (en) * 2018-03-08 2023-08-23 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
JP7501920B2 (ja) 2019-02-27 2024-06-18 国立大学法人 鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた鎮痒薬
EP4147701A4 (en) 2020-05-08 2024-06-12 Kagoshima University Antidepressant/anxiolytic drug in which pac1 receptor antagonist is used
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
EP0393607B1 (en) 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives having a hetero ring
AU688102B2 (en) * 1994-08-30 1998-03-05 Sankyo Company Limited Isoxazoles
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
AU709323B2 (en) 1996-03-15 1999-08-26 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
WO2000059285A2 (en) * 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
CN1222254C (zh) * 2000-02-10 2005-10-12 波滕西亚医疗公司 用无线能量源进行尿失禁治疗
US7442165B2 (en) * 2000-02-14 2008-10-28 Obtech Medical Ag Penile prosthesis
TWI286132B (en) * 2002-09-20 2007-09-01 Hoffmann La Roche 4-pyrrolidino-phenyl-benzyl ether derivatives
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism

Also Published As

Publication number Publication date
KR100676014B1 (ko) 2007-01-30
CA2496756C (en) 2012-01-10
HK1083498A1 (zh) 2006-07-07
CN100503562C (zh) 2009-06-24
PE20050079A1 (es) 2005-03-01
NO20050701L (no) 2005-03-02
JO2604B1 (en) 2011-11-01
ATE459601T1 (de) 2010-03-15
AU2003273901A1 (en) 2004-04-08
WO2004026827A1 (en) 2004-04-01
CA2498335A1 (en) 2004-04-01
US7122562B2 (en) 2006-10-17
PE20050078A1 (es) 2005-02-28
EP1542971A1 (en) 2005-06-22
CN1681777A (zh) 2005-10-12
MXPA05002880A (es) 2005-05-27
AR041297A1 (es) 2005-05-11
JP2006503833A (ja) 2006-02-02
HRP20050262A2 (en) 2006-06-30
GT200300205A (es) 2004-04-29
ES2344557T3 (es) 2010-08-31
NZ538049A (en) 2007-05-31
JP4335140B2 (ja) 2009-09-30
DE60333202D1 (de) 2010-08-12
HK1083499A1 (zh) 2006-07-07
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
EP1542970B1 (en) 2010-06-30
UY27993A1 (es) 2004-03-31
WO2004026825A1 (en) 2004-04-01
ZA200501557B (en) 2005-09-08
ZA200501137B (en) 2006-12-27
BRPI0314631B1 (pt) 2018-04-17
PA8583501A1 (es) 2004-04-23
TWI331994B (en) 2010-10-21
CN100383118C (zh) 2008-04-23
EP1542969A1 (en) 2005-06-22
NO330012B1 (no) 2011-02-07
AU2003270213B8 (en) 2009-03-05
CA2498785A1 (en) 2004-04-01
WO2004026826A1 (en) 2004-04-01
HRP20050261A2 (en) 2006-05-31
US20060122235A1 (en) 2006-06-08
NO20050652L (no) 2005-03-08
RU2336268C2 (ru) 2008-10-20
ES2338646T3 (es) 2010-05-11
JP4335141B2 (ja) 2009-09-30
DK1542970T3 (da) 2010-08-02
HRP20050263A2 (en) 2006-12-31
CY1110745T1 (el) 2015-06-10
JP2006510596A (ja) 2006-03-30
RU2005111969A (ru) 2006-01-20
CN1681778A (zh) 2005-10-12
PE20050077A1 (es) 2005-03-01
TWI337604B (en) 2011-02-21
GT200300206A (es) 2004-04-29
CA2498785C (en) 2011-07-26
JP2006503834A (ja) 2006-02-02
HK1084383A1 (en) 2006-07-28
DE60331559D1 (de) 2010-04-15
RU2336267C2 (ru) 2008-10-20
RU2005111968A (ru) 2006-11-10
NZ538048A (en) 2007-05-31
PT1542970E (pt) 2010-07-19
TWI286132B (en) 2007-09-01
ATE472530T1 (de) 2010-07-15
US20040116707A1 (en) 2004-06-17
BR0314631A (pt) 2005-08-02
PL376019A1 (en) 2005-12-12
KR100676015B1 (ko) 2007-01-30
MY135696A (en) 2008-06-30
AU2003270213A1 (en) 2004-04-08
JO2605B1 (en) 2011-11-01
AU2003273901B2 (en) 2008-07-10
TW200408624A (en) 2004-06-01
TW200413350A (en) 2004-08-01
AR041299A1 (es) 2005-05-11
KR20050057450A (ko) 2005-06-16
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
BR0314299A (pt) 2005-12-13
CA2496756A1 (en) 2004-04-01
PL376018A1 (en) 2005-12-12
SI1542970T1 (sl) 2010-08-31
AU2003267381B2 (en) 2009-08-27
ZA200501311B (en) 2006-10-25
RU2323209C2 (ru) 2008-04-27
KR20050057466A (ko) 2005-06-16
TW200410935A (en) 2004-07-01
US7037935B2 (en) 2006-05-02
NZ538046A (en) 2007-08-31
JP4335142B2 (ja) 2009-09-30
RU2005111974A (ru) 2006-01-20
PA8583001A1 (es) 2004-04-23
US7151111B2 (en) 2006-12-19
PA8583601A1 (es) 2004-09-16
UY27990A1 (es) 2004-03-31
UY27991A1 (es) 2004-03-31
US20040106650A1 (en) 2004-06-03
PL376021A1 (en) 2005-12-12
NO329754B1 (no) 2010-12-13
NO20050665L (no) 2005-04-18
AR041298A1 (es) 2005-05-11
KR20050057456A (ko) 2005-06-16
US7235581B2 (en) 2007-06-26
CN100400509C (zh) 2008-07-09
HRP20050263B1 (hr) 2013-09-30
US20040097578A1 (en) 2004-05-20
AU2003267381A1 (en) 2004-04-08
KR100681586B1 (ko) 2007-02-09
AU2003270213B2 (en) 2009-02-12
MY133332A (en) 2007-11-30
GT200300204A (es) 2004-04-29
CN1681779A (zh) 2005-10-12
MY134480A (en) 2007-12-31
MXPA05002878A (es) 2005-05-27

Similar Documents

Publication Publication Date Title
BR0314299A (pt) Derivados de pirrolidona como inibidores de mao-b
BRPI0409109A (pt) novos compostos
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR0312232A (pt) Inibidores de caspases e seus usos
BRPI0409622A (pt) derivados tricìclicos de indol e o seu uso no tratamento da doença de alzheimer
BR0316350A (pt) Diaminotriazóis úteis como inibidores de proteìna cinases
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
CY1111070T1 (el) Παραγωγα 2-αμινο-κουιναζολινης χρησιμα ως αναστολεις της β-σεκρετασης (bace)
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
TW200800957A (en) New compounds
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR0212929A (pt) Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade
BRPI0519106A2 (pt) compostos, uso destes, processo para sua fabricaÇço, composiÇÕes farmacÊuticas, mÉtodo para o tratamento e/ou profilaxia de doenÇas que sço associadas com a dpp-iv
BRPI0514133A (pt) compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i
BRPI0414948A (pt) derivados de pirazolo-e-imidazo pirimidina
BRPI0409454A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com o receptor de glucagon e sua utilização
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
BRPI0417833A (pt) novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
BRPI0416238A (pt) compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa)
BR0308786A (pt) Derivados de ftalimido como inibidores da monoamina oxidase b

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.